Comment on

• Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

  Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, Stewart D, Ruether JD, Morris D, Glick S, Gyonyor E, Andersson BS. Russell JA, et al. Biol Blood Marrow Transplant. 2002;8(9):468-76. doi: 10.1053/bbmt.2002.v8.pm12374451. Biol Blood Marrow Transplant. 2002. PMID: 12374451 Clinical Trial.
• Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

  Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Andersson BS, et al. Biol Blood Marrow Transplant. 2002;8(9):477-85. doi: 10.1053/bbmt.2002.v8.pm12374452. Biol Blood Marrow Transplant. 2002. PMID: 12374452 Clinical Trial.
• Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.

  Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Fernandez HF, et al. Biol Blood Marrow Transplant. 2002;8(9):486-92. doi: 10.1053/bbmt.2002.v8.pm12374453. Biol Blood Marrow Transplant. 2002. PMID: 12374453 Clinical Trial.
• Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.

  Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS. Kashyap A, et al. Biol Blood Marrow Transplant. 2002;8(9):493-500. doi: 10.1053/bbmt.2002.v8.pm12374454. Biol Blood Marrow Transplant. 2002. PMID: 12374454 Clinical Trial.